Evidence map›Paper›PMID 37631942›Full record

ArticleVaccines2023

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod-Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC).

Tjalf Ziemssen, Marie Groth, Veronika Eva Winkelmann, Tobias Bopp

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Tjalf ZiemssenDepartment of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Technische Universität Dresden, 01307 Dresden, Germany.ORCID 0000-0001-8799-8202
Marie GrothNovartis Pharma GmbH, 90429 Nuremberg, Germany.
Veronika Eva WinkelmannNovartis Pharma GmbH, 90429 Nuremberg, Germany.
Tobias BoppInstitute for Immunology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
Novartis (Germany) · DEJohannes Gutenberg University Mainz · DEUniversity Hospital Carl Gustav Carus · DE

Funding

Novartis Pharma GmbH not applicable
6 · The paper itself

Abstract

backgroundEvidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is rare.

methodsAMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 mRNA vaccination during ongoing siponimod treatment (cohort 1), during siponimod interruption (cohort 2), or during treatment with other disease-modifying therapies or without therapy (cohort 3). SARS-CoV-2-specific antibodies and T-cell reactivity were measured six months after the initial vaccination and one month after the booster.

results41 patients were recruited into cohort 1 (

conclusionsThe antibody and T-cell responses support SARS-CoV-2 (booster) vaccines in siponimod-treated patients.

Indexed as

COVID-19 vaccinationdisease-modifying therapyneutralizing antibodiessecondary progressive multiple sclerosisT-cell response

Identifiers

PMID37631942
PMCPMC10459882
OpenAlexW4385994627

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.